Literature DB >> 28605498

Effect of Home Blood Pressure on Inducing Remission/Regression of Microalbuminuria in Patients With Type 2 Diabetes Mellitus.

Motonobu Nishimura1, Yasuhisa Kato2, Tsuyoshi Tanaka3, Hideki Taki4, Atsuhito Tone5, Kazunori Yamada6, Seiji Suzuki7, Miho Saito8, Yutaka Ando9, Yoshiharu Hoshiyama10.   

Abstract

BACKGROUND: The Home Blood Pressure for Diabetic Nephropathy study is a prospective observational study conducted to determine the effect of home blood pressure (HBP) on remission/regression of microalbuminuria in patients with type 2 diabetes mellitus (DM).
METHODS: Patients with type 2 DM having microalbuminuria were followed-up for 3 years. Remission of microalbuminuria was defined as shift from microalbuminuria to normoalbuminuria. Regression of microalbuminuria was defined as a 50% reduction in urinary albumin-creatinine ratio from baseline. All measurements of morning and evening HBP were averaged every year and defined as all HBP.
RESULTS: In total, 235 patients were followed up. The 3-year cumulative incidences of remission and regression were 32.3% and 44.7%, respectively. Following analysis of all cases, the degree of decline in all home systolic blood pressure (AHSBP), rather than mean AHSBP, influenced the incidence of remission/regression. There was a strong relationship between the decline in AHSBP during the follow-up period and AHSBP at baseline. Therefore, separate analyses of the patients with AHSBP below 140 mm Hg at baseline were performed, which revealed that mean AHSBP during the follow-up period independently affected the incidence of remission/regression. The hazard ratio for inducing remission/regression was significantly lower in patients with AHSBP during the follow-up period above 130 mm Hg than in those with AHSBP below 120 mm Hg.
CONCLUSIONS: Optimal AHSBP for the induction of remission/regression of microalbuminuria might be below 130 mm Hg. It is required to confirm whether keeping AHSBP below 130 mm Hg leads to subsequent renoprotection or not. CLINICAL TRIALS REGISTRATION: Trial Number UMIN000000804. © American Journal of Hypertension, Ltd 2017. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  blood pressure; diabetic nephropathy; home blood pressure; hypertension; microalbuminuria; regression; remission

Mesh:

Substances:

Year:  2017        PMID: 28605498     DOI: 10.1093/ajh/hpx050

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  3 in total

1.  Diabetic nephropathy ameliorated in patients with normal home blood pressure compared to those with isolated high home systolic blood pressure: A 5-year prospective cohort study among patients with type 2 diabetes mellitus.

Authors:  Nobuko Kitagawa; Emi Ushigome; Noriyuki Kitagawa; Hidetaka Ushigome; Isao Yokota; Naoko Nakanishi; Masahide Hamaguchi; Mai Asano; Masahiro Yamazaki; Michiaki Fukui
Journal:  Diab Vasc Dis Res       Date:  2022 May-Jun       Impact factor: 3.541

2.  An Observational Registry to Assess Urinary Albumin Evolution in Saudi Hypertensive Patients with the Current Treatment Local algorithm: Results of the RATIONAL Study.

Authors:  Mostafa Qaid Al Shamiri; Saeed M G Al-Ghamdi; Rafif M Farahat; Hosam Nasr El Desouki; Mohammed Saeed ElNazer; Hossam El Deen Moustafa Saleh; Ashraf Abdulghani Abo El Naga; Adil Mohammed Salih; Khedr Abdul Aal Mahmoud; Nasim Ahmad Ahmad
Journal:  Int J Nephrol Renovasc Dis       Date:  2020-04-23

3.  Factors influencing home blood pressure monitor ownership in a large clinical trial.

Authors:  Thineskrishna Anbarasan; Amy Rogers; David A Rorie; J W Kerr Grieve; Robert W V Flynn; Thomas M MacDonald; Isla S Mackenzie
Journal:  J Hum Hypertens       Date:  2021-03-02       Impact factor: 3.012

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.